Business Description
RAPT Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US75382E1091
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 19.12 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.05 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -15 | |||||
3-Year EPS without NRI Growth Rate | -11.7 | |||||
3-Year FCF Growth Rate | -14.8 | |||||
3-Year Book Growth Rate | 0.5 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 0.07 | |||||
9-Day RSI | 2.23 | |||||
14-Day RSI | 9.36 | |||||
6-1 Month Momentum % | -10.74 | |||||
12-1 Month Momentum % | -75.6 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 9.9 | |||||
Quick Ratio | 9.9 | |||||
Cash Ratio | 9.45 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.6 | |||||
Shareholder Yield % | -11.15 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -82.01 | |||||
ROA % | -70.3 | |||||
ROIC % | -699.14 | |||||
ROC (Joel Greenblatt) % | -1651.28 | |||||
ROCE % | -85.14 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.63 | |||||
Price-to-Tangible-Book | 0.63 | |||||
EV-to-EBIT | 0.28 | |||||
EV-to-Forward-EBIT | -0.04 | |||||
EV-to-EBITDA | 0.28 | |||||
EV-to-Forward-EBITDA | -0.04 | |||||
EV-to-Forward-Revenue | 242.61 | |||||
EV-to-FCF | 0.32 | |||||
Price-to-Net-Current-Asset-Value | 0.67 | |||||
Price-to-Net-Cash | 0.71 | |||||
Earnings Yield (Greenblatt) % | 357.14 | |||||
FCF Yield % | -166.68 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
RAPT Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -2.553 | ||
Beta | 0.28 | ||
Volatility % | 154.31 | ||
14-Day RSI | 9.36 | ||
14-Day ATR (€) | 0.090168 | ||
20-Day SMA (€) | 2.474 | ||
12-1 Month Momentum % | -75.6 | ||
52-Week Range (€) | 1.42 - 24.2 | ||
Shares Outstanding (Mil) | 34.96 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
RAPT Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
RAPT Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
RAPT Therapeutics Inc Frequently Asked Questions
What is RAPT Therapeutics Inc(FRA:0RA)'s stock price today?
When is next earnings date of RAPT Therapeutics Inc(FRA:0RA)?
Does RAPT Therapeutics Inc(FRA:0RA) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |